Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular (NASDAQ: LMAT) delivers innovative medical devices for vascular surgeons worldwide. This page provides centralized access to official announcements, financial disclosures, and strategic developments from the leader in peripheral vascular disease solutions.
Investors and medical professionals will find timely updates on product launches, regulatory milestones, and financial results. Track advancements in carotid shunts, vascular grafts, and other devices critical to open vascular surgery.
Our curated news collection enables you to monitor LMAT's progress in addressing circulatory challenges through cutting-edge technologies. Discover updates on manufacturing expansions, clinical study outcomes, and partnerships shaping the future of vascular care.
Bookmark this page for direct access to verified information about LeMaitre Vascular's surgical innovations and market leadership. Check regularly for new developments impacting the medical device sector and patient care standards.
LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.